CTX130 – CAR T Cell Therapy Offers New Hope for Advanced Clear Cell Renal Cell Carcinoma: AACR 2024

Renal cell carcinoma (RCC) is the most common type of kidney cancer, characterized by various subtypes like clear cell, papillary, chromophore, and collecting duct carcinomas. Clear cell carcinoma, constituting 80% of all RCC cases commands the majority of treatment focus due to its predominance.

Currently, the primary treatment revolves around checkpoint inhibitors (CPIs) and tyrosine kinase inhibitors (TKIs). However, prognosis takes a downturn when patients progress on these drug classes, highlighting the pressing need for innovative solutions.

At AACR 2024, findings from a Phase 1 (COBALT-RCC) trial investigating allogeneic CAR T cell treatment (CTX130) in patients with advanced clear cell renal cell carcinoma are encouraging.CTX130 uses T cells from healthy donors edited to target CD70 and to disrupt the TRAC and β2M genes, which should reduce graft vs. host disease and donor rejection.

Long-term follow-up and translational data from the COBALT-RCC study underscore the promising antitumor activity and remarkable safety profile of CTX130 in advanced ccRCC patients. Impressively, 81% of patients experienced clinical benefit CR/partial response/SD), with 75% exhibiting stable disease and one individual achieving a durable complete response lasting over three years—a landmark achievement in allogeneic, off-the-shelf CAR T cell therapy for refractory solid tumors.

Building upon these findings, CRISPR Therapeutics has developed CTX131, an improved version of CTX130. Currently, patients are being enrolled in a Phase I/II clinical trial (NCT05795595) to evaluate the potential of this novel therapy in adult patients with relapsed/refractory solid tumors.

For more information, refer DelveInsight’s report:
Advanced Renal Cell Carcinoma (RCC) – Market Insight, Epidemiology And Market Forecast – 2032